J&J/Cordis’ Cypher DES threatened by supplier dispute
This article was originally published in The Gray Sheet
Wyeth sues Johnson & Johnson Oct. 26 in Delaware federal court, seeking to break an agreement to supply J&J's Cordis unit with sirolimus - the drug used on the Cypher drug-eluting stent. The suit alleges material breach of contract and seeks damages, charging Cordis with failing to make "commercially reasonable" efforts to develop CCI 779 - a drug analogous to sirolimus - as required under their agreement. Cordis denies the charges. A Wyeth spokesperson told "The Gray Sheet" that "if they don't act on [the agreement] over a period of time and they languish, [they should] terminate it so that we can find another partner." Wyeth advised Cordis of the charges in writing April 14, according to the complaint. Sirolimus is marketed by Wyeth as Rapamune...
You may also be interested in...
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.